- Home
- QLGN vs CDT Comparison
QLGN vs CDT Comparison
Compare QLGN & CDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QLGN
- CDT
- Stock Information
- Founded
- QLGN 1996
- CDT 2019
- Country
- QLGN United States
- CDT United States
- Employees
- QLGN N/A
- CDT N/A
- Industry
- QLGN Biotechnology: Pharmaceutical Preparations
- CDT Biotechnology: Pharmaceutical Preparations
- Sector
- QLGN Health Care
- CDT Health Care
- Exchange
- QLGN Nasdaq
- CDT Nasdaq
- Market Cap
- QLGN 4.7M
- CDT 5.2M
- IPO Year
- QLGN N/A
- CDT N/A
- Fundamental
- Price
- QLGN $2.80
- CDT $2.00
- Analyst Decision
- QLGN
- CDT
- Analyst Count
- QLGN 0
- CDT 0
- Target Price
- QLGN N/A
- CDT N/A
- AVG Volume (30 Days)
- QLGN 2.5M
- CDT 357.8K
- Earning Date
- QLGN 07-21-2025
- CDT 08-11-2025
- Dividend Yield
- QLGN N/A
- CDT N/A
- EPS Growth
- QLGN N/A
- CDT N/A
- EPS
- QLGN N/A
- CDT N/A
- Revenue
- QLGN N/A
- CDT N/A
- Revenue This Year
- QLGN N/A
- CDT N/A
- Revenue Next Year
- QLGN N/A
- CDT N/A
- P/E Ratio
- QLGN N/A
- CDT N/A
- Revenue Growth
- QLGN N/A
- CDT N/A
- 52 Week Low
- QLGN $2.74
- CDT $1.94
- 52 Week High
- QLGN $13.50
- CDT $622.50
- Technical
- Relative Strength Index (RSI)
- QLGN 35.34
- CDT 30.01
- Support Level
- QLGN $2.77
- CDT $1.94
- Resistance Level
- QLGN $3.29
- CDT $2.31
- Average True Range (ATR)
- QLGN 0.53
- CDT 0.15
- MACD
- QLGN -0.06
- CDT 0.05
- Stochastic Oscillator
- QLGN 1.65
- CDT 10.91
About QLGN Qualigen Therapeutics Inc.
Qualigen Therapeutics Inc is an early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's program, QN-302, is an investigational small-molecule G-quadruplexes (G4)-selective transcription inhibitor with binding affinity to G4s prevalent in cancer cells.
About CDT Conduit Pharmaceuticals Inc.
Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being prioritized by biopharmaceutical companies to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready for autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor, and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.